Eton Pharmaceuticals (ETON) Q2 FY26 earnings call

Eton Pharmaceuticals delivered a strong second quarter, marked by record revenue and significant margin expansion driven by broad-based portfolio strength and the successful Hemangiol relaunch. The company strategically expanded its pediatric dermatology franchise through the acquisition of Impavido and licensing of ASN001, positioning itself for future growth without external financing. Management is focused on leveraging its commercial infrastructure to build leadership in rare disease therapies and expects continued momentum.